Scinai Secures $5.1M CDMO Deal with U.S. Biopharma Client

Event summary

Scinai's CDMO subsidiary inked a $5.1M development and clinical manufacturing agreement with a Nasdaq-listed U.S. biopharma firm.
Committed Customer Orders surged 300% to $7.6M from year-end 2025.
Potential additional clinical manufacturing could add $5.85M in service fees through early 2028.
Services include CMC development, IND-enabling activities, and clinical manufacturing for an oncology product.
Stability services will continue beyond 2027, providing long-term revenue visibility.

The big picture

This deal represents Scinai's strategic pivot toward CDMO services as a growth driver alongside its therapeutic development platform. The 300% increase in committed orders demonstrates growing demand for outsourced manufacturing capabilities in the biopharma sector. The potential for additional clinical and commercial manufacturing highlights how these relationships can scale over time, providing long-term revenue visibility.

What we're watching

Revenue Realization: How Scinai will convert committed orders into actual revenue given performance-based payment terms.
Capacity Utilization: Whether Scinai can maintain high facility utilization rates as new projects come online.
Commercial Manufacturing: The pace at which the relationship could evolve into commercial manufacturing agreements.